Table 3.

Postdiagnostic nonvigorous activity, vigorous activity, walking duration, and walking pace in relation to risk of prostate cancer progression among 1,455 men diagnosed with clinically localized prostate cancer

Nonvigorous (h/wk)0–0.91.0–2.93.0–4.95.0–9.9≥10.0Ptrenda
Events/person-year22/45634/77413/26923/69725/554
Model 1 HR (95% CI)b1.00.91 (0.53–1.55)0.97 (0.49–1.93)0.73 (0.40–1.31)0.96 (0.54–1.70)0.89
Model 2 HR (95% CI)c1.00.78 (0.45–1.33)0.84 (0.42–1.69)0.61 (0.34–1.11)0.87 (0.49–1.56)0.98
Model 3 HR (95% CI)d1.00.80 (0.45–1.40)0.90 (0.44–1.83)0.71 (0.38–1.32)0.96 (0.52–1.76)0.76
Vigorous (h/wk)0.00.1–1.241.25–2.9≥3.0Ptrenda
Events/person-year66/1,38925/64316/38410/334
Model 1 HR (95% CI)b1.00.81 (0.51–1.28)0.93 (0.54–1.60)0.62 (0.32–1.21)0.19
Model 2 HR (95% CI)c1.00.88 (0.55–1.39)0.84 (0.48–1.45)0.63 (0.32–1.23)0.17
Model 3 HR (95% CI)d1.00.88 (0.55–1.41)0.71 (0.40–1.28)0.69 (0.35–1.36)0.19
Walking duration (h/wk)0–0.40.5–1.41.5–3.94.0–6.9≥7.0Ptrenda
Events/person-year25/51538/85123/50716/47515/402
Model 1 HR (95% CI)b1.00.95 (0.57–1.58)0.98 (0.55–1.73)0.79 (0.42–1.48)0.89 (0.47–1.68)0.95
Model 2 HR (95% CI)c,e1.00.91 (0.53–1.54)1.12 (0.62–2.05)0.91 (0.46–1.77)0.98 (0.50–1.92)0.99
Model 3 HR (95% CI)d,e1.00.81 (0.47–1.40)0.94 (0.51–1.75)0.74 (0.38–1.45)0.80 (0.41–1.58)0.86
Walking pace (mph)eEasy (<2.0)Normal (2.0–2.9)Brisk (≥3.0)Ptrenda
Events/person-year27/41762/1,34826/971
Model 1 HR (95% CI)b1.00.80 (0.50–1.26)0.50 (0.28–0.86)0.01
Model 2 HR (95% CI)c1.00.94 (0.58–1.50)0.52 (0.29–0.91)0.01
Model 3 HR (95% CI)d1.00.96 (0.60–1.56)0.56 (0.32–1.00)0.02
  • aCalculated by using the median of each category as a continuous term.

  • bModel 1 adjusted for age at diagnosis (continuous) and time from diagnosis to questionnaire (continuous).

  • cModel 2 adjusted for covariates in model 1 plus primary treatment (radical prostatectomy, radiation, other/watchful waiting, hormone), biopsy Gleason sum (<7, 7, >7), and PSA at diagnosis (tertiles). Vigorous and nonvigorous activities were adjusted for each other and walking duration and walking pace were adjusted for each other.

  • dModel 3 adjusted for covariates in model 2 plus BMI (<25, 25–29.9, ≥30 kg/m2); 43 participants (3%) with missing BMI were not included.

  • eTen participants (0.7%) who reported being unable to walk and reported no time spent walking were excluded from models with walking pace.